Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
<b>Background:</b> Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data mining from FAERS...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2025-01-01
|
| Seri Bilgileri: | Pharmaceuticals |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1424-8247/18/1/114 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|